$RMTG
Regenerative Medical Technology Group Inc. Stock $rmtg

$rmtg Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023064856 Filed on August 09, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$646.8K	$361.4K	$304.5K
YoY Change	72.78%	18.66%	1831.14%
Cost Of Revenue	$196.5K	$107.5K	$155.9K
YoY Change	79.71%	-31.01%	1214.34%
Gross Profit	$450.3K	$253.8K	$148.6K
YoY Change	69.93%	70.76%	3702.51%
Gross Profit Margin	69.62%	70.24%	48.81%
Selling, General & Admin	$426.7K	$626.8K	$478.7K
YoY Change	10.2%	30.93%	85.4%
% of Gross Profit	94.76%	246.94%	322.07%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$98.67K	$57.88K	$35.33K
YoY Change	147.4%	63.84%	17562.5%
% of Gross Profit	21.91%	22.8%	23.77%
Operating Expenses	$525.4K	$684.7K	$514.1K
YoY Change	23.01%	33.19%	98.92%
Operating Profit	-$75.06K	-$430.8K	-$365.4K
YoY Change	-53.69%	17.9%	43.57%
Interest Expense	-$1.657M	-$1.599M	$1.131M
YoY Change	-240.02%	-241.39%	156.82%
% of Operating Profit
Other Income/Expense, Net	-$1.658M	-$1.600M	-$1.131M
YoY Change		41.48%	389.46%
Pretax Income	-$5.857M	-$2.030M	-$1.493M
YoY Change	335.68%	35.98%	61.22%
Income Tax
% Of Pretax Income
Net Earnings	-$5.857M	-$2.030M	-$1.493M
YoY Change	335.68%	35.98%	61.22%
Net Earnings / Revenue	-905.52%	-561.83%	-490.3%
Basic Earnings Per Share	-$0.47	-$0.16	-$0.12
Diluted Earnings Per Share	-$0.47	-$0.16	-$0.12
COMMON SHARES
Basic Shares Outstanding	12.44M shares	12.44M shares	12.22M shares
Diluted Shares Outstanding	12.44M shares	12.44M shares	12.22M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.144M	$1.225M	$1.925M
YoY Change	-35.36%	-36.34%	-81.66%
Cash & Equivalents	$1.144M	$1.225M	$1.925M
Short-Term Investments
Other Short-Term Assets	$10.75K		$0.00
YoY Change
Inventory
Prepaid Expenses	$10.75K
Receivables	$35.01K	$51.26K	$23.03K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.190M	$1.276M	$1.948M
YoY Change	-35.9%	-34.46%	-81.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$147.8K	$130.7K	$159.1K
YoY Change	1.89%	-17.85%	8741.5%
Goodwill	$1.680M	$5.805M	$5.805M
YoY Change	-71.06%	0.0%
Intangibles	$280.9K	$305.3K	$403.3K
YoY Change	-25.81%	-24.29%
Long-Term Investments
YoY Change
Other Assets	$5.570K	$5.570K	$5.570K
YoY Change	0.0%	0.0%	-96.82%
Total Long-Term Assets	$2.125M	$6.266M	$6.422M
YoY Change	-66.67%	-2.44%	3532.42%
TOTAL ASSETS
Total Short-Term Assets	$1.190M	$1.276M	$1.948M
Total Long-Term Assets	$2.125M	$6.266M	$6.422M
Total Assets	$3.315M	$7.542M	$8.370M
YoY Change	-59.73%	-9.89%	-23.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$367.1K	$336.9K	$230.0K
YoY Change	31.4%	46.45%	181.18%
Accrued Expenses	$7.081M	$6.238M	$3.470M
YoY Change	69.01%	79.75%	279.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$16.97M	$7.094M	$1.533M
YoY Change	1008.08%	362.74%
Total Short-Term Liabilities	$24.43M	$13.69M	$5.298M
YoY Change	302.07%	158.42%	363.0%
LONG-TERM LIABILITIES
Long-Term Debt	$421.2K	$9.533M	$12.71M
YoY Change	-96.8%	-25.0%	98.86%
Other Long-Term Liabilities	$0.00	$0.00	$16.14K
YoY Change	-100.0%	-100.0%
Total Long-Term Liabilities	$421.2K	$9.533M	$12.73M
YoY Change	-96.8%	-25.09%	99.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.43M	$13.69M	$5.298M
Total Long-Term Liabilities	$421.2K	$9.533M	$12.73M
Total Liabilities	$24.85M	$23.22M	$18.03M
YoY Change	29.24%	28.85%	139.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$61.73M	-$55.88M	-$49.84M
YoY Change	20.61%	12.11%
Common Stock	$12.44K	$12.44K	$12.25K
YoY Change	1.58%	1.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$21.54M	-$15.68M	-$9.656M
YoY Change
Total Liabilities & Shareholders Equity	$3.315M	$7.542M	$8.370M
YoY Change	-59.73%	-9.89%	-23.36%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$5.857M	-$2.030M	-$1.493M
YoY Change	335.68%	35.98%	61.22%
Depreciation, Depletion And Amortization	$98.67K	$57.88K	$35.33K
YoY Change	147.4%	63.84%	17562.5%
Cash From Operating Activities	$10.14K	-$406.7K	-$396.4K
YoY Change	-106.66%	2.6%	-27.17%
INVESTING ACTIVITIES
Capital Expenditures	$91.38K	$4.720K	-$128.6K
YoY Change	-7352.38%	-103.67%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$91.38K	-$4.720K	-$128.6K
YoY Change	7152.38%	-96.33%	-48.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	-11.42K
YoY Change	-100.0%	-100.0%	-100.11%
NET CHANGE
Cash From Operating Activities	10.14K	-406.7K	-396.4K
Cash From Investing Activities	-91.38K	-4.720K	-128.6K
Cash From Financing Activities	0.000	0.000	-11.42K
Net Change In Cash	-81.24K	-411.4K	-536.5K
YoY Change	-47.55%	-23.31%	-105.53%
FREE CASH FLOW
Cash From Operating Activities	$10.14K	-$406.7K	-$396.4K
Capital Expenditures	$91.38K	$4.720K	-$128.6K
Free Cash Flow	-$81.24K	-$411.4K	-$267.8K
YoY Change	-46.17%	53.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12154532	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12216471	shares
CY2023Q2	mssv	Settlement Of Lawsuit SettlementOfLawsuit		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-56010
	dei	Entity Registrant Name EntityRegistrantName	MESO NUMISMATICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-0492191
	dei	Entity Address Address Line1 EntityAddressAddressLine1	433 Plaza Real Suite 275
	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33432
	dei	City Area Code CityAreaCode	(800)
	dei	Local Phone Number LocalPhoneNumber	889-9509
	dei	Security12b Title Security12bTitle	None
	dei	Trading Symbol TradingSymbol	None
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12443938	shares
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1225190	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1645185	usd
CY2023Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	51261	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	49766	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	1276451	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1694951	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	130743	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	186269	usd
CY2023Q2	us-gaap	Other Assets OtherAssets	5568	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	5568	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	305314	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	354084	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18638	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33963	usd
CY2023Q2	us-gaap	Goodwill Goodwill	5805438	usd
CY2022Q4	us-gaap	Goodwill Goodwill	5805438	usd
CY2023Q2	us-gaap	Assets Assets	7542152	usd
CY2022Q4	us-gaap	Assets Assets	8080273	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	336884	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	245463	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6237875	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4657530	usd
CY2023Q2	us-gaap	Customer Advances Current CustomerAdvancesCurrent	500	usd
CY2022Q4	us-gaap	Customer Advances Current CustomerAdvancesCurrent	10450	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	4019	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	6944	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	18638	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	32568	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	7093698	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	7046666	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	13691614	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11999621	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1395	usd
CY2023Q2	mssv	Convertible Notes Payable Net Of Discount ConvertibleNotesPayableNetOfDiscount	30547	usd
CY2022Q4	mssv	Convertible Notes Payable Net Of Discount ConvertibleNotesPayableNetOfDiscount	37419	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	7800	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	7800	usd
CY2023Q2	mssv	Notes Payable Net Of Discount NotesPayableNetOfDiscount	9494953	usd
CY2022Q4	mssv	Notes Payable Net Of Discount NotesPayableNetOfDiscount	8016330	usd
CY2023Q2	us-gaap	Liabilities Liabilities	23224914	usd
CY2022Q4	us-gaap	Liabilities Liabilities	20062565	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	6500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	6500000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14046252	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14046252	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12443938	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12443938	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	12444	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	12444	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40180669	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40180669	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55876935	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52176465	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-15682762	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11982292	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7542152	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8080273	usd
CY2023Q2	us-gaap	Revenues Revenues	361359	usd
CY2022Q2	us-gaap	Revenues Revenues	297522	usd
	us-gaap	Revenues Revenues	1147557	usd
	us-gaap	Revenues Revenues	596270	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	107535	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	150552	usd
	us-gaap	Cost Of Revenue CostOfRevenue	356932	usd
	us-gaap	Cost Of Revenue CostOfRevenue	343035	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	253824	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	146970	usd
	us-gaap	Gross Profit GrossProfit	790625	usd
	us-gaap	Gross Profit GrossProfit	253235	usd
CY2023Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	114811	usd
CY2022Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	80956	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	256448	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	135497	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	255411	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	196330	usd
	us-gaap	Professional Fees ProfessionalFees	464783	usd
	us-gaap	Professional Fees ProfessionalFees	592069	usd
CY2023Q2	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	22500	usd
CY2022Q2	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	22500	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	45000	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	45000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	57875	usd
CY2022Q2	us-gaap	Depreciation Depreciation	35125	usd
	us-gaap	Depreciation Depreciation	114503	usd
	us-gaap	Depreciation Depreciation	61902	usd
CY2023Q2	mssv	Investor Relations InvestorRelations	2250	usd
CY2022Q2	mssv	Investor Relations InvestorRelations	47634	usd
	mssv	Investor Relations InvestorRelations	4500	usd
	mssv	Investor Relations InvestorRelations	94884	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	231818	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	130047	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	410443	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	231894	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	684665	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	512592	usd
	us-gaap	Operating Expenses OperatingExpenses	1295677	usd
	us-gaap	Operating Expenses OperatingExpenses	1161246	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1600380	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1131178	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3200806	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2271708	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	998	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	3527	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2925	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	9606	usd
	mssv	Settlement Of Lawsuit SettlementOfLawsuit	2463	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2030223	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1493273	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3700470	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3170113	usd
CY2022Q2	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	208	usd
	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	84	usd
CY2022Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	208	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	84	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2030223	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1493065	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3700470	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3170029	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.16
CY2022Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.12
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.3
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.26
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.3
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12443938	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12216471	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12443938	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12154532	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11982292	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3700470	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-15682762	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-13652539	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2030223	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-15682762	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-6757007	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	20000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	251536	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3170029	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-9655500	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-8172435	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1493065	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-9655500	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3700470	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3170113	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1531096	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	884430	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	114503	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	61902	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	2925	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	9606	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2463	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1495	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5771	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2714	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1661816	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1323429	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-399938	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-913015	usd
	mssv	Depreciation Discontinued Operations DepreciationDiscontinuedOperations	400	usd
	mssv	Gainloss On Discontinued Operations GainlossOnDiscontinuedOperations	84	usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	484	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-399938	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-912531	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10207	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	128639	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10207	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-128639	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	9850	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	12823	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9850	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-12823	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-419995	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1053993	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1645185	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2978525	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1225190	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1924532	usd
	us-gaap	Interest Paid Net InterestPaidNet	207	usd
	mssv	Issuance Of Preferred Series Dd For Acquisitions IssuanceOfPreferredSeriesDDForAcquisitions	251536	usd
	us-gaap	Stock Issued1 StockIssued1	20000	usd
CY2017Q3	mssv	Share Issuance Of Series Bb Preferred ShareIssuanceOfSeriesBBPreferred	25000	shares
CY2018Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On July 2, 2018, the Board of Directors authorized and shareholders approved a 1-for-1,000 reverse stock split of its issued and outstanding shares of common stock held by the holders of record. The prior year financials have been changed to reflect the 1-for-1,000 reverse stock split.
CY2021Q3	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	50000	usd
CY2022Q4	mssv	Interest Percentages InterestPercentages	1	pure
CY2022	us-gaap	Liabilities Average Amount Outstanding LiabilitiesAverageAmountOutstanding	68313	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Use of Estimates in Financial Statement Presentation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The significant estimates included in these financial statements are associated with accounting for the goodwill, derivative liability, valuation of preferred stock, and for the valuation of assets and liabilities in business combination.</p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Reclassifications</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts for the prior year have been revised or reclassified to conform to the current year presentation. No change in net loss resulted from these reclassifications.</p>
	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2023Q2	mssv	Convertible Notes Outstanding ConvertibleNotesOutstanding	212646	shares
CY2022Q4	mssv	Convertible Notes Outstanding ConvertibleNotesOutstanding	365463	shares
CY2023Q2	mssv	Convertible Preferred Stock Outstanding ConvertiblePreferredStockOutstanding	39447283	shares
CY2022Q4	mssv	Convertible Preferred Stock Outstanding ConvertiblePreferredStockOutstanding	39447283	shares
CY2023Q2	mssv	Shares Underlying Warrants Outstanding SharesUnderlyingWarrantsOutstanding	103500000	shares
CY2022Q4	mssv	Shares Underlying Warrants Outstanding SharesUnderlyingWarrantsOutstanding	103500000	shares
CY2023Q2	mssv	Total Outstanding TotalOutstanding	143159929	shares
CY2022Q4	mssv	Total Outstanding TotalOutstanding	143312746	shares
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	4019	usd
CY2023Q2	us-gaap	Financial Instruments Owned At Fair Value FinancialInstrumentsOwnedAtFairValue	4019	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	6944	usd
CY2022Q4	us-gaap	Financial Instruments Owned At Fair Value FinancialInstrumentsOwnedAtFairValue	6944	usd
	mssv	Going Concern GoingConcern	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Going Concern</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, resulting in an accumulated deficit of $55,876,935 and a working capital deficit of $12,415,163 as of June 30, 2023 and future losses are anticipated. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ability of the Company to continue its operations as a going concern is dependent on management’s plans, which include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will require additional funding to finance the growth of its current and expected future operations as well to achieve its strategic objectives. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</p>
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55876935	usd
CY2023Q2	mssv	Working Capital Deficit WorkingCapitalDeficit	12415163	usd
	us-gaap	Revenues Revenues	1147557	usd
	us-gaap	Revenues Revenues	596270	usd
	us-gaap	Revenues Revenues	1147557	usd
	us-gaap	Cost Of Revenue CostOfRevenue	356932	usd
	mssv	Revenue Gross Profits RevenueGrossProfits	790625	usd
	mssv	Gross Profits GrossProfits	0.689	pure
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Deferred Revenue BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue	7542152	usd
	us-gaap	Profit Loss ProfitLoss	-3700470	usd
CY2019Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.2
CY2019Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	81043	shares
CY2019Q4	mssv	Aggregate Exchange Amount AggregateExchangeAmount	97252	usd
	us-gaap	Line Of Credit Facility Maximum Amount Outstanding During Period LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod	9850	usd
CY2022	us-gaap	Line Of Credit Facility Maximum Amount Outstanding During Period LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod	15000	usd
	us-gaap	Deferred Policy Acquisition Cost Amortization Expense Other DeferredPolicyAcquisitionCostAmortizationExpenseOther	5441	usd
CY2022	us-gaap	Deferred Policy Acquisition Cost Amortization Expense Other DeferredPolicyAcquisitionCostAmortizationExpenseOther	18437	usd
	mssv	Outstanding Convertible Notes OutstandingConvertibleNotes	9850	usd
CY2022	mssv	Outstanding Convertible Notes OutstandingConvertibleNotes	15000	usd
CY2015	mssv	Maturity Term MaturityTerm	P1Y
CY2019Q4	mssv	Premium Paid PremiumPaid	0.20	pure
CY2020Q4	mssv	Shares Exchanged SharesExchanged	5379624	usd
CY2020Q4	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	5379624	usd
CY2020Q4	us-gaap	Stock Issued During Period Shares Employee Stock Ownership Plan StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan	15000000	shares
CY2020Q4	mssv	Aggregate Principal Amount AggregatePrincipalAmount	5379624	usd
CY2020Q4	mssv	Debt Instrument Bears Interest Rate DebtInstrumentBearsInterestRate	0.15	pure
CY2020Q4	mssv	Cashless Warrants Purchased CashlessWarrantsPurchased	15000000	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.03
CY2020Q4	mssv	Warrants Issued WarrantsIssued	15000000	shares
CY2020	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	262376	usd
	mssv	Aggregate Loan Balances Outstanding AggregateLoanBalancesOutstanding	5379624	usd
CY2022	mssv	Aggregate Loan Balances Outstanding AggregateLoanBalancesOutstanding	5379624	usd
CY2023Q2	mssv	Unamortized Discount UnamortizedDiscount	40855	usd
CY2022Q4	mssv	Unamortized Discount UnamortizedDiscount	81700	usd
CY2020Q4	mssv	Promissory Bebentures Lender Amount PromissoryBebenturesLenderAmount	110000	usd
CY2020Q4	mssv	Annual Interest Rate AnnualInterestRate	0.15	pure
CY2020Q4	mssv	Cashless Warrants Purchased CashlessWarrantsPurchased	1000000	shares
CY2020Q4	mssv	Advanced Total AdvancedTotal	100000	usd
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	10000	usd
CY2020Q4	mssv	Warrants Issued WarrantsIssued	1000000	shares
CY2020Q4	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	17491	usd
CY2021Q1	mssv	Promissory Bebentures Lender Amount PromissoryBebenturesLenderAmount	1000000	usd
CY2021Q1	mssv	Annual Interest Rate AnnualInterestRate	0.15	pure
CY2021Q1	mssv	Cashless Warrants Purchased CashlessWarrantsPurchased	10000000	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.03
CY2021Q1	mssv	Advanced Total AdvancedTotal	900000	usd
CY2021Q1	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	100000	usd
CY2021Q1	mssv	Warrants Issued WarrantsIssued	10000000	shares
CY2021Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	237811	usd
CY2021Q2	mssv	Promissory Bebentures Lender Amount PromissoryBebenturesLenderAmount	11600000	usd
CY2021Q2	mssv	Annual Interest Rate AnnualInterestRate	0.12	pure
CY2021Q2	mssv	Cashless Warrants Purchased CashlessWarrantsPurchased	70000000	shares
CY2021Q2	mssv	Advanced Total AdvancedTotal	10500000	usd
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	1100000	usd
CY2021Q2	mssv	Warrants Issued WarrantsIssued	70000000	shares
CY2021Q2	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	5465726	usd
CY2021Q3	us-gaap	Loans And Leases Receivable Gross Carrying Amount LoansAndLeasesReceivableGrossCarryingAmount	20991	usd
CY2021Q3	mssv	Interest Rate InterestRate	0.0899	pure
CY2021Q3	mssv	Interest Monthly Payments InterestMonthlyPayments	504.94	usd
CY2021Q3	mssv	Promissory Bebentures Lender Amount PromissoryBebenturesLenderAmount	1100000	usd
CY2021Q3	mssv	Annual Interest Rate AnnualInterestRate	0.12	pure
CY2021Q3	mssv	Cashless Warrants Purchased CashlessWarrantsPurchased	7500000	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.085
CY2021Q3	mssv	Advanced Total AdvancedTotal	1000000	usd
CY2021Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	100000	usd
CY2021Q3	mssv	Warrants Issued WarrantsIssued	7500000	shares
CY2021Q3	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	360607	usd
	mssv	Outstanding Loan OutstandingLoan	7958	usd
CY2022	mssv	Outstanding Loan OutstandingLoan	7958	usd
CY2023Q2	mssv	Participating Mortgage Loan Unamortized Debt Discount Amount ParticipatingMortgageLoanUnamortizedDebtDiscountAmount	20	usd
CY2022Q4	mssv	Participating Mortgage Loan Unamortized Debt Discount Amount ParticipatingMortgageLoanUnamortizedDebtDiscountAmount	139	usd
CY2021Q4	mssv	Promissory Bebentures Lender Amount PromissoryBebenturesLenderAmount	84000	usd
CY2021Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	22162	usd
CY2021Q4	mssv	Premium Percent PremiumPercent	0.05	pure
CY2021	us-gaap	Premiums Earned Net Life PremiumsEarnedNetLife	111470	usd
CY2021	mssv	Debt Instrument Bears Interest Rate DebtInstrumentBearsInterestRate	0.12	pure
	mssv	Promissory Notes Payable PromissoryNotesPayable	20229759	usd
CY2022	mssv	Promissory Notes Payable PromissoryNotesPayable	20229759	usd
CY2023Q2	mssv	Notes Payablerelated Parties Non Current NotesPayablerelatedPartiesNonCurrent	7800	usd
CY2022Q4	mssv	Notes Payablerelated Parties Non Current NotesPayablerelatedPartiesNonCurrent	7800	usd
	mssv	Promissory Notes Payable Discount PromissoryNotesPayableDiscount	3608506	usd
CY2022	mssv	Promissory Notes Payable Discount PromissoryNotesPayableDiscount	5117631	usd
CY2023Q2	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	32602	usd
CY2022Q4	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	49132	usd
CY2023Q2	us-gaap	Notes Payable NotesPayable	16596451	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	15070796	usd
	us-gaap	Dividends Share Based Compensation Cash DividendsShareBasedCompensationCash	0	usd
CY2022	us-gaap	Dividends Share Based Compensation Cash DividendsShareBasedCompensationCash	5776	usd
	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	1580345	usd
CY2022	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	2898155	usd
CY2023Q2	us-gaap	Amortization Expense Per Dollar Of Gross Revenue AmortizationExpensePerDollarOfGrossRevenue	1525654	usd
CY2022Q4	us-gaap	Amortization Expense Per Dollar Of Gross Revenue AmortizationExpensePerDollarOfGrossRevenue	1738327	usd
CY2023Q2	mssv	Outstanding Promissory Notes Payable OutstandingPromissoryNotesPayable	20237559	usd
CY2022Q4	mssv	Outstanding Promissory Notes Payable OutstandingPromissoryNotesPayable	20237559	usd
	mssv	Common Stock Issuablein Shares CommonStockIssuableinShares	212646	shares
	mssv	Market Value Of Common Stock On Measurement Datein Dollars MarketValueOfCommonStockOnMeasurementDateinDollars	0.0189
	mssv	Adjusted Exercise Pricein Dollars Per Share AdjustedExercisePriceinDollarsPerShare	0.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0496	pure
	mssv	Instrument Lives In Years InstrumentLivesInYears	P1Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.72	pure
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	20442	usd
CY2022Q4	mssv	Gain On Derivative Instruments GainOnDerivativeInstruments	10856	usd
CY2022	mssv	Derivative Instruments Conversions DerivativeInstrumentsConversions	2642	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	6944	usd
CY2023Q2	mssv	Gain On Derivative Instruments GainOnDerivativeInstruments	1577	usd
	mssv	Derivative Instruments Conversions DerivativeInstrumentsConversions	1348	usd
CY2023Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	4019	usd
CY2020	mssv	Issuance Of Warrants IssuanceOfWarrants	16000000	shares
CY2021Q1	mssv	Issuance Of Warrants IssuanceOfWarrants	10000000	shares
CY2021Q1	mssv	Warrants Issued For Debt WarrantsIssuedForDebt	237811	usd
CY2021Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.1
CY2021Q2	mssv	Issuance Of Warrants IssuanceOfWarrants	70000000	shares
CY2021Q2	mssv	Warrants Issued For Debt WarrantsIssuedForDebt	5465726	usd
CY2021Q3	mssv	Issuance Of Warrants IssuanceOfWarrants	7500000	shares
CY2021Q3	mssv	Warrants Issued For Debt WarrantsIssuedForDebt	360607	usd
CY2014Q2	us-gaap	Preferred Units Issued PreferredUnitsIssued	1000000	shares
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	mssv	Aggregate Vote AggregateVote	0.67	pure
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2023Q2	mssv	Averages Transactions Percentage AveragesTransactionsPercentage	0.30	pure
CY2021Q3	mssv	Final Payment FinalPayment	225000	usd
CY2021Q3	mssv	Final Payment FinalPayment	50000	usd
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000	shares
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	mssv	Payment Amount PaymentAmount	225000	usd
CY2021Q3	mssv	Payment Amount PaymentAmount	50000	usd
CY2022Q1	mssv	Annual Rate AnnualRate	90000	usd
	us-gaap	Other Expenses OtherExpenses	503552	usd
CY2022Q1	mssv	Annual Rate AnnualRate	90000	usd
CY2022Q1	mssv	Issuance Of Shares IssuanceOfShares	896	shares
CY2021Q3	mssv	Issuance Of Shares IssuanceOfShares	448	shares
CY2022Q1	mssv	Issuance Of Shares IssuanceOfShares	448	shares
CY2023Q2	us-gaap	Payments For Fees PaymentsForFees	45000	usd
CY2022	us-gaap	Payments For Fees PaymentsForFees	90000	usd
CY2021Q3	mssv	Stock Purchase Percentage StockPurchasePercentage	1	pure
CY2019Q1	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	20991	usd
CY2019Q1	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan	504.94	usd
	mssv	Outstanding Auto Loan OutstandingAutoLoan	0	usd
CY2022	mssv	Outstanding Auto Loan OutstandingAutoLoan	0	usd
	mssv	Aggregates Amount AggregatesAmount	133470	usd
CY2022	mssv	Aggregates Amount AggregatesAmount	200390	usd
	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Assets EffectiveIncomeTaxRateReconciliationDispositionOfAssets	0.275	pure
CY2023Q2	us-gaap	Area Of Land AreaOfLand	1647	sqm
	us-gaap	Payments For Rent PaymentsForRent	2714	usd
CY2023Q2	us-gaap	Security Deposit SecurityDeposit	5588	usd
CY2023Q2	us-gaap	Prepaid Rent PrepaidRent	21744	usd
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	44097	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	161868	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	96135	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	130743	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	186269	usd
	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	65733	usd
CY2022	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	55199	usd
CY2023Q2	us-gaap	Finite Lived Trademarks Gross FiniteLivedTrademarksGross	87700	usd
CY2022Q4	us-gaap	Finite Lived Trademarks Gross FiniteLivedTrademarksGross	87700	usd
	mssv	Intellectual Property Licenses IntellectualPropertyLicenses	363000	usd
CY2022	mssv	Intellectual Property Licenses IntellectualPropertyLicenses	363000	usd
	mssv	Customer Base CustomerBase	37000	usd
CY2022	mssv	Customer Base CustomerBase	37000	usd
CY2023Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	487700	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	487700	usd
CY2023Q2	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	182386	usd
CY2022Q4	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	133616	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	305314	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	354084	usd
CY2023Q2	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
	mssv	Amortization Expense Intellectual Property AmortizationExpenseIntellectualProperty	48770	usd
CY2022	mssv	Amortization Expense Intellectual Property AmortizationExpenseIntellectualProperty	97540	usd
	mssv	Monthly Rent MonthlyRent	2714	usd
CY2023Q2	us-gaap	Security Deposit Liability SecurityDepositLiability	5588	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	16284	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2714	usd
CY2023Q2	mssv	Total Undiscounted Cash Payments TotalUndiscountedCashPayments	18998	usd
CY2023Q2	us-gaap	Receivable With Imputed Interest Net Amount ReceivableWithImputedInterestNetAmount	360	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	18638	usd
CY2021Q3	mssv	Stock Purchase Agreement Percentage StockPurchaseAgreementPercentage	1	pure
CY2021Q3	us-gaap	Cash Cash	225000	usd
	us-gaap	Goodwill Change In Goodwill Allocation Description GoodwillChangeInGoodwillAllocationDescription	The preliminary purchase price for the merger was determined to be $6.229 million, which consists of (i) 1 million shares of Series AA preferred stock valued at approximately $964,000, (ii) 8,974 shares of Series DD preferred stock valued at approximately $5.04 million and (iii) $225,000 in cash of which $175,000 was advanced prior to closing of the transaction.
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	5805438	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	5805438	usd
CY2023Q2	us-gaap	Goodwill Gross GoodwillGross	5805438	usd
CY2022Q4	mssv	Interest Percentage InterestPercentage	1	pure
	us-gaap	Discontinued Operation Amount Of Adjustment To Prior Period Gain Loss On Disposal Net Of Tax DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax	84	usd
	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	18329	usd
	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	16439	usd
	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	1890	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	78	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	400	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1328	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	1806	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	84	usd
CY2023Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax		usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12443938	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12443938	shares
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
	mssv	Depreciation Discontinued Operations DepreciationDiscontinuedOperations		usd
	mssv	Gainloss On Discontinued Operations GainlossOnDiscontinuedOperations		usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	mssv	Issuance Of Preferred Series Dd For Acquisitions IssuanceOfPreferredSeriesDDForAcquisitions		usd
	mssv	Expected Dividend Yields ExpectedDividendYields
CY2022	us-gaap	Servicing Asset At Fair Value Additions ServicingAssetAtFairValueAdditions		usd
	us-gaap	Servicing Asset At Fair Value Additions ServicingAssetAtFairValueAdditions		usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001760026

Files In Submission

Name	View Source	Status
0001213900-23-064856-index-headers.html	Edgar Link	pending
0001213900-23-064856-index.html	Edgar Link	pending
0001213900-23-064856.txt	Edgar Link	pending
0001213900-23-064856-xbrl.zip	Edgar Link	pending
f10q0623ex31-1_mesonumis.htm	Edgar Link	pending
f10q0623ex31-2_mesonumis.htm	Edgar Link	pending
f10q0623ex32-1_mesonumis.htm	Edgar Link	pending
f10q0623_mesonumis.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mssv-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
mssv-20230630_def.xml	Edgar Link	unprocessable
mssv-20230630_lab.xml	Edgar Link	unprocessable
mssv-20230630_pre.xml	Edgar Link	unprocessable
f10q0623_mesonumis_htm.xml	Edgar Link	completed
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mssv-20230630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RMTG
Regenerative Medical Technology Group Inc. Stock $rmtg

2023 Q3 Form 10-Q Financial Statement

#000121390023064856 Filed on August 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTG Regenerative Medical Technology Group Inc. Stock $rmtg

2023 Q3 Form 10-Q Financial Statement

#000121390023064856 Filed on August 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTG
Regenerative Medical Technology Group Inc. Stock $rmtg